Vivace Therapeutics
Vivace Therapeutics is a small molecule drug discovery and development company focusing on targeting the Hippo pathway to treat human carcinomas. Their lead product, VT3989, is a first-in-class TEAD autopalmitoylation inhibitor showing promising results in mesothelioma patients. The company is advancing VT3989 toward a registrational Phase 3 clinical trial.
Funding Round: Series D
Funding Amount: $35M
Date: 12-Mar-2025
Investors: RA Capital Management, Canaan Partners, Cenova Capital
Markets: Biotech, Oncology, Therapeutics
HQ: San Mateo, California, United States
Founded: 2014
Website: http://www.vivacetherapeutics.com/
LinkedIn: https://www.linkedin.com/company/vivace-therapeutics-inc-
Crunchbase: https://www.crunchbase.com/organization/vivace-therapeutics
Leave a Comment
Comments
No comments yet.